Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

EClinicalMedicine · 2025 · PMC12572812 · PMID 41181834

Europe PMC DOI

hedged sentences

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

did not reach statistical significanceP = 0.063so close (0.05 < p ≤ 0.1)

At 8 weeks, the increase in mean LBM was greater in Group A (+0.99 kg; 95% CI +0.34 to +1.64) compared to Group N (+0.14 kg; −0.49 to +0.77), but the between-group difference did not reach statistical significance (P = 0.063).

also in 111,027 other papers

showed a trendno p-value reported

Interpretation Although no significant difference was observed between the two groups in the primary endpoint, anamorelin showed a trend toward increased LBM with good tolerability, suggesting potential benefit in gastric cancer cachexia.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.